Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2015 | Pages:
473 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Metastatic Pancreatic Cancer - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Metastatic Pancreatic Cancer - Pipeline Review, H2 2015', provides an overview of the Metastatic Pancreatic Cancer's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Metastatic Pancreatic Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Pancreatic Cancer and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Pancreatic Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Metastatic Pancreatic Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Metastatic Pancreatic Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Metastatic Pancreatic Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Pancreatic Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Metastatic Pancreatic Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Metastatic Pancreatic Cancer Overview 10 Therapeutics Development 11 Pipeline Products for Metastatic Pancreatic Cancer - Overview 11 Pipeline Products for Metastatic Pancreatic Cancer - Comparative Analysis 12 Metastatic Pancreatic Cancer - Therapeutics under Development by Companies 13 Metastatic Pancreatic Cancer - Therapeutics under Investigation by Universities/Institutes 18 Metastatic Pancreatic Cancer - Pipeline Products Glance 19 Late Stage Products 19 Clinical Stage Products 20 Early Stage Products 21 Metastatic Pancreatic Cancer - Products under Development by Companies 22 Metastatic Pancreatic Cancer - Products under Investigation by Universities/Institutes 27 Metastatic Pancreatic Cancer - Companies Involved in Therapeutics Development 28 AbbVie Inc. 28 Aduro BioTech, Inc. 29 ArQule, Inc. 30 Array BioPharma Inc. 31 AstraZeneca Plc 32 AVEO Pharmaceuticals, Inc. 33 Axcentua Pharmaceuticals AB 34 Biothera, Inc. 35 Boehringer Ingelheim GmbH 36 Boston Biomedical, Inc. 37 Bristol-Myers Squibb Company 38 Cantex Pharmaceuticals, Inc. 39 Celgene Corporation 40 Clovis Oncology, Inc. 41 Cornerstone Pharmaceuticals, Inc. 42 CTI BioPharma Corp. 43 CytRx Corporation 44 Eleison Pharmaceuticals, Inc. 45 Eli Lilly and Company 46 Ensol Biosciences Inc. 47 Erytech Pharma SA 48 F. Hoffmann-La Roche Ltd. 49 Fountain Biopharma Inc. 50 Gilead Sciences, Inc. 51 GlaxoSmithKline Plc 52 Halozyme Therapeutics, Inc. 53 HanAll Biopharma Co., Ltd. 54 Immodulon Therapeutics Ltd. 55 Immunomedics, Inc. 56 Incyte Corporation 57 MabVax Therapeutics Holdings, Inc. 58 MedImmune, LLC 59 Merck & Co., Inc. 60 Merrimack Pharmaceuticals, Inc. 61 NanoCarrier Co., Ltd. 62 Nanotherapeutics, Inc. 63 NantKwest, Inc. 64 Natco Pharma Limited 65 NewLink Genetics Corporation 66 Novartis AG 67 Oncolytics Biotech Inc. 68 Oncovir, Inc. 69 Oryx GmbH & Co. KG 70 Pfizer Inc. 71 Pharma Mar, S.A. 72 Pharmacyclics, Inc. 73 Phoenix Biotechnology, Inc. 74 Precision Biologics, Inc. 75 Redx Pharma Plc 76 Rexahn Pharmaceuticals, Inc. 77 Sanofi 78 Silence Therapeutics Plc 79 Targovax AS 80 Teva Pharmaceutical Industries Limited 81 Verlyx Pharma Inc. 82 Zeria Pharmaceutical Co., Ltd. 83 Metastatic Pancreatic Cancer - Therapeutics Assessment 84 Assessment by Monotherapy Products 84 Assessment by Combination Products 85 Assessment by Target 86 Assessment by Mechanism of Action 91 Assessment by Route of Administration 95 Assessment by Molecule Type 97 Drug Profiles 99 acalabrutinib - Drug Profile 99 aldoxorubicin hydrochloride - Drug Profile 102 alpelisib - Drug Profile 105 aNK Program - Drug Profile 107 ARQ-761 - Drug Profile 110 asparaginase - Drug Profile 111 Atu-027 - Drug Profile 113 AXP-10711 - Drug Profile 115 bevacizumab - Drug Profile 117 BI-853520 - Drug Profile 123 binimetinib - Drug Profile 124 Cellular Immunotherapy for Cancer - Drug Profile 129 Cellular Immunotherapy to Target CD3 and EGFR for Oncology - Drug Profile 130 CEP-37250 - Drug Profile 131 Charis-1000 - Drug Profile 132 CIM-1 - Drug Profile 133 cisplatin - Drug Profile 134 clivatuzumab tetraxetan - Drug Profile 136 CPI-613 - Drug Profile 138 CRS-207 - Drug Profile 141 CX-01 - Drug Profile 144 durvalumab + tremelimumab - Drug Profile 146 ensituximab - Drug Profile 148 erismodegib - Drug Profile 150 FB-704A - Drug Profile 153 ficlatuzumab - Drug Profile 154 galunisertib - Drug Profile 157 glufosfamide - Drug Profile 159 GS-5745 - Drug Profile 162 GSK-2256098 - Drug Profile 163 haNK Program - Drug Profile 165 HL-178 - Drug Profile 167 HuMab-5B1 - Drug Profile 168 ibrutinib - Drug Profile 169 IMM-101 - Drug Profile 176 Imprime PGG - Drug Profile 178 INCB-39110 - Drug Profile 183 indoximod - Drug Profile 185 irinotecan hydrochloride - Drug Profile 187 landogrozumab - Drug Profile 190 lapatinib ditosylate - Drug Profile 191 LCL-161 - Drug Profile 195 LGK-974 - Drug Profile 197 lurbinectedin - Drug Profile 198 LY-2109761 - Drug Profile 201 MesoCART - Drug Profile 202 MK-2206 - Drug Profile 203 MK-2206 + selumetinib sulfate - Drug Profile 206 MM-141 - Drug Profile 208 Monoclonal Antibody Conjugated to Target Mesothelin for Oncology - Drug Profile 209 napabucasin - Drug Profile 211 nimotuzumab - Drug Profile 214 NRCAN-019 - Drug Profile 218 olaparib - Drug Profile 220 paclitaxel albumin bound - Drug Profile 224 paclitaxel lipsomal - Drug Profile 228 palbociclib - Drug Profile 230 Parvoryx - Drug Profile 234 PBI-05204 - Drug Profile 235 PCI-27483 - Drug Profile 237 PEGPH-20 - Drug Profile 239 pelareorep - Drug Profile 241 pentamidine isethionate - Drug Profile 246 plerixafor - Drug Profile 248 Poly-ICLC - Drug Profile 250 PRI-724 - Drug Profile 253 rottlerin - Drug Profile 255 rucaparib phosphate - Drug Profile 256 ruxolitinib phosphate - Drug Profile 259 RX-0201 - Drug Profile 264 SGT-53 - Drug Profile 266 Small Molecule to Inhibit Porcupine for Cancer - Drug Profile 268 Small Molecules to Inhibit Lysyl Oxidase for Metastatic Pancreatic Cancer - Drug Profile 269 TG-01 - Drug Profile 270 TL-118 - Drug Profile 272 tosedostat - Drug Profile 274 trametinib dimethyl sulfoxide - Drug Profile 276 Triapine - Drug Profile 279 ulocuplumab - Drug Profile 281 Vaccine for Oncology - Drug Profile 283 veliparib - Drug Profile 284 Z-360 - Drug Profile 288 Metastatic Pancreatic Cancer - Recent Pipeline Updates 290 Metastatic Pancreatic Cancer - Dormant Projects 451 Metastatic Pancreatic Cancer - Discontinued Products 454 Metastatic Pancreatic Cancer - Product Development Milestones 457 Featured News & Press Releases 457 Appendix 466 Methodology 466 Coverage 466 Secondary Research 466 Primary Research 466 Expert Panel Validation 466 Contact Us 466 Disclaimer 467
List of Tables
Number of Products under Development for Metastatic Pancreatic Cancer, H2 2015 17 Number of Products under Development for Metastatic Pancreatic Cancer - Comparative Analysis, H2 2015 18 Number of Products under Development by Companies, H2 2015 20 Number of Products under Development by Companies, H2 2015 (Contd..1) 21 Number of Products under Development by Companies, H2 2015 (Contd..2) 22 Number of Products under Development by Companies, H2 2015 (Contd..3) 23 Number of Products under Investigation by Universities/Institutes, H2 2015 24 Comparative Analysis by Late Stage Development, H2 2015 25 Comparative Analysis by Clinical Stage Development, H2 2015 26 Comparative Analysis by Early Stage Development, H2 2015 27 Products under Development by Companies, H2 2015 28 Products under Development by Companies, H2 2015 (Contd..1) 29 Products under Development by Companies, H2 2015 (Contd..2) 30 Products under Development by Companies, H2 2015 (Contd..3) 31 Products under Development by Companies, H2 2015 (Contd..4) 32 Products under Investigation by Universities/Institutes, H2 2015 33 Metastatic Pancreatic Cancer - Pipeline by AbbVie Inc., H2 2015 34 Metastatic Pancreatic Cancer - Pipeline by Aduro BioTech, Inc., H2 2015 35 Metastatic Pancreatic Cancer - Pipeline by ArQule, Inc., H2 2015 36 Metastatic Pancreatic Cancer - Pipeline by Array BioPharma Inc., H2 2015 37 Metastatic Pancreatic Cancer - Pipeline by AstraZeneca Plc, H2 2015 38 Metastatic Pancreatic Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H2 2015 39 Metastatic Pancreatic Cancer - Pipeline by Axcentua Pharmaceuticals AB, H2 2015 40 Metastatic Pancreatic Cancer - Pipeline by Biothera, Inc., H2 2015 41 Metastatic Pancreatic Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2015 42 Metastatic Pancreatic Cancer - Pipeline by Boston Biomedical, Inc., H2 2015 43 Metastatic Pancreatic Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2015 44 Metastatic Pancreatic Cancer - Pipeline by Cantex Pharmaceuticals, Inc., H2 2015 45 Metastatic Pancreatic Cancer - Pipeline by Celgene Corporation, H2 2015 46 Metastatic Pancreatic Cancer - Pipeline by Clovis Oncology, Inc., H2 2015 47 Metastatic Pancreatic Cancer - Pipeline by Cornerstone Pharmaceuticals, Inc., H2 2015 48 Metastatic Pancreatic Cancer - Pipeline by CTI BioPharma Corp., H2 2015 49 Metastatic Pancreatic Cancer - Pipeline by CytRx Corporation, H2 2015 50 Metastatic Pancreatic Cancer - Pipeline by Eleison Pharmaceuticals, Inc., H2 2015 51 Metastatic Pancreatic Cancer - Pipeline by Eli Lilly and Company, H2 2015 52 Metastatic Pancreatic Cancer - Pipeline by Ensol Biosciences Inc., H2 2015 53 Metastatic Pancreatic Cancer - Pipeline by Erytech Pharma SA, H2 2015 54 Metastatic Pancreatic Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 55 Metastatic Pancreatic Cancer - Pipeline by Fountain Biopharma Inc., H2 2015 56 Metastatic Pancreatic Cancer - Pipeline by Gilead Sciences, Inc., H2 2015 57 Metastatic Pancreatic Cancer - Pipeline by GlaxoSmithKline Plc, H2 2015 58 Metastatic Pancreatic Cancer - Pipeline by Halozyme Therapeutics, Inc., H2 2015 59 Metastatic Pancreatic Cancer - Pipeline by HanAll Biopharma Co., Ltd., H2 2015 60 Metastatic Pancreatic Cancer - Pipeline by Immodulon Therapeutics Ltd., H2 2015 61 Metastatic Pancreatic Cancer - Pipeline by Immunomedics, Inc., H2 2015 62 Metastatic Pancreatic Cancer - Pipeline by Incyte Corporation, H2 2015 63 Metastatic Pancreatic Cancer - Pipeline by MabVax Therapeutics Holdings, Inc., H2 2015 64 Metastatic Pancreatic Cancer - Pipeline by MedImmune, LLC, H2 2015 65 Metastatic Pancreatic Cancer - Pipeline by Merck & Co., Inc., H2 2015 66 Metastatic Pancreatic Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2015 67 Metastatic Pancreatic Cancer - Pipeline by NanoCarrier Co., Ltd., H2 2015 68 Metastatic Pancreatic Cancer - Pipeline by Nanotherapeutics, Inc., H2 2015 69 Metastatic Pancreatic Cancer - Pipeline by NantKwest, Inc., H2 2015 70 Metastatic Pancreatic Cancer - Pipeline by Natco Pharma Limited, H2 2015 71 Metastatic Pancreatic Cancer - Pipeline by NewLink Genetics Corporation, H2 2015 72 Metastatic Pancreatic Cancer - Pipeline by Novartis AG, H2 2015 73 Metastatic Pancreatic Cancer - Pipeline by Oncolytics Biotech Inc., H2 2015 74 Metastatic Pancreatic Cancer - Pipeline by Oncovir, Inc., H2 2015 75 Metastatic Pancreatic Cancer - Pipeline by Oryx GmbH & Co. KG, H2 2015 76 Metastatic Pancreatic Cancer - Pipeline by Pfizer Inc., H2 2015 77 Metastatic Pancreatic Cancer - Pipeline by Pharma Mar, S.A., H2 2015 78 Metastatic Pancreatic Cancer - Pipeline by Pharmacyclics, Inc., H2 2015 79 Metastatic Pancreatic Cancer - Pipeline by Phoenix Biotechnology, Inc., H2 2015 80 Metastatic Pancreatic Cancer - Pipeline by Precision Biologics, Inc., H2 2015 81 Metastatic Pancreatic Cancer - Pipeline by Redx Pharma Plc, H2 2015 82 Metastatic Pancreatic Cancer - Pipeline by Rexahn Pharmaceuticals, Inc., H2 2015 83 Metastatic Pancreatic Cancer - Pipeline by Sanofi, H2 2015 84 Metastatic Pancreatic Cancer - Pipeline by Silence Therapeutics Plc, H2 2015 85 Metastatic Pancreatic Cancer - Pipeline by Targovax AS, H2 2015 86 Metastatic Pancreatic Cancer - Pipeline by Teva Pharmaceutical Industries Limited, H2 2015 87 Metastatic Pancreatic Cancer - Pipeline by Verlyx Pharma Inc., H2 2015 88 Metastatic Pancreatic Cancer - Pipeline by Zeria Pharmaceutical Co., Ltd., H2 2015 89 Assessment by Monotherapy Products, H2 2015 90 Assessment by Combination Products, H2 2015 91 Number of Products by Stage and Target, H2 2015 93 Number of Products by Stage and Mechanism of Action, H2 2015 98 Number of Products by Stage and Route of Administration, H2 2015 102 Number of Products by Stage and Molecule Type, H2 2015 104 Metastatic Pancreatic Cancer Therapeutics - Recent Pipeline Updates, H2 2015 296 Metastatic Pancreatic Cancer - Dormant Projects, H2 2015 457 Metastatic Pancreatic Cancer - Dormant Projects (Contd..1), H2 2015 458 Metastatic Pancreatic Cancer - Dormant Projects (Contd..2), H2 2015 459 Metastatic Pancreatic Cancer - Discontinued Products, H2 2015 460 Metastatic Pancreatic Cancer - Discontinued Products (Contd..1), H2 2015 461 Metastatic Pancreatic Cancer - Discontinued Products (Contd..2), H2 2015 462
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
